Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?
letter
OA: closed
CC0
Abstract
This letter discusses the article "The Effects of Rituximab on Experimental Endometriosis Model in Rats" by Dogan et al., which evaluated the potential therapeutic efficacy of rituximab in an experimental animal model of endometriosis. While the study showed promising results in decreasing the volume of endometriotic implants and differences in B-cell count and fibrosis score, rituximab is typically used as a therapy for B lymphocyte malignancies and has potential short-term and long-term side effects. Additionally, animal models for endometriosis have limitations, and novel models are still being developed. Therefore, further preclinical research is necessary to evaluate the safety and efficacy of rituximab as a potential treatment for endometriosis in humans.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
References (5)
- Endometriosis: pathogenesis and treatment via openalex
- Investigational drugs for the treatment of endometriosis, an update on recent developments via openalex
- The effects of Rituximab on experimental endometriosis model in rats via openalex
- Translational animal models for endometriosis research: a long and windy road via openalex
- W2133205391 via openalex
Source provenance
- europepmc
- last seen: 2026-06-14T06:08:20.186862+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-14T06:07:17.833701+00:00
- unpaywall
- last seen: 2026-06-14T06:15:46.576397+00:00
License: CC0
· commercial use OK